Diabetes Mellitus, Type 2, Prediabetic State
Conditions
Keywords
sphingolipid, diabetes mellitus, biomarker, obesity, insulin resistance
Brief summary
This study is designed to compare the serum sphingolipidomic analyses in healthy, pre-diabetic and diabetic subjects. age, sex and BMI are matched among these three groups. As ceramide, sphingosine, sphingosine-1-phosphate and sphinganine are involved in inflammation, immunity and cancer, investigators proposed a hypothesis that sphingosine-1-phosphate and other sphingolipids may be associated with the progress of type 2 diabetes. sphingolipids may be a biomarker for diabetes.
Detailed description
The first purpose of this study is to determine whether serum sphingolipid metabolites associate significantly with the weight among type 2 diabetes. 60 patients with diagnosed type 2 diabetes will be recruited. The serum concentrations of sphingolipid metabolites of 20 type 2 diabetic patients with obesity will be compared to age- and sex-matched series of 40 type 2 patients without obesity. The second purpose of this study is to determine whether serum sphingolipid metabolites associate significantly with the process and severity of type 2 diabetes. The serum concentrations of sphingolipid metabolites of 20 subjects with type 2 diabetes will be compared to age-, sex- and BMI-matched series of healthy and pre-diabetic subjects. Investigators speculate that the serum concentration of sphingolipid metabolites are positively related with the progression of diabetes. In order to discover why serum sphingolipid metabolites correlates with the progression of diabetes, detailed information on HbA1c, duration of diabetes history and insulin resistance defined by homeostatic model assessment (HOMA-IR) will be analysed. These three parameters may affect the serum concentrations of sphingolipid metabolites.
Interventions
OTHERdiabetes
the exposure of interests are obesity, diabetes and insulin-resistance
Sponsors
Chinese Medical Association
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* clinical diagnosis of diabetes mellitus, type 2 * clinical diagnosis of prediabetic status * older than 18 and younger than 90 years-old * clinical diagnosis of insulin-resistance * clinical diagnosis of newly onset of diabetes mellitus, type 2 * those who are willing to participate in the trial and sign the consent form
Exclusion criteria
* any cardiovascular disease (myocardial infarction, heart failure, cerebrovascular accident) * missing information of BMI * sever liver, kidney dysfunction * sever pancreatitis or those who received pancreatectomy * on medications of hormone, immunosuppressive therapy or drugs that may affect the bioactivity or concentration of sphingolipids (e.g. asprin ) * patients on pregnancy * sever systematic diseases including carcinoma, mental disorder, sever anemia et al.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum concentration of sphingosine-1-phosphate, micromol per liter | Nov, 2016 |
Secondary
| Measure | Time frame |
|---|---|
| serum concentration of sphingosine, micromol per liter | Nov, 2016 |
| serum concentration of sphinganine-1-phosphate, micromol per liter | Nov, 2016 |
| serum concentration of sphinganine, micromol per liter | Nov, 2016 |
| serum concentration of ceramide, micromol per liter | Nov, 2016 |
Countries
China
Contacts
Primary ContactJing Sui
Outcome results
None listed